MELİS GÜL GÜLSAR ÇAYCI OĞUZHAN SATILMIŞ SİNAN DEMİRCİOGLU ATAKAN TEKİNALP
Journal of Current Hematology & Oncology Research - 2025;3(3):74-76
Cytarabine, a commonly used antimetabolite in hematologic malignancies, has various side effects, including dermatological toxicity. A 61-year-old male with relapsed diffuse large B-cell lymphoma (DLBCL) was started on the MATRIX regimen, including high-dose cytarabine. On the third day of treatment, he developed a palmar rash, which later progressed to petechiae and purpura on the trunk, back, and lower extremities. No systemic corticosteroid treatment was administered, and the rash gradually resolved by the 13th day. This case highlights a rare dermatological reaction to cytarabine. Although cutaneous toxicity of cytarabine is uncommon, clinicians should be aware of its potential manifestations and manage patients symptomatically to avoid unnecessary interventions while ensuring treatment continuation.
